​​

​​​​​​​​​​​​​​​​ASCO 2023​

Focus on DLBCL

​ ​​​

Treatment Efficacy & Safety in Elderly Patients With DLBCL​

In a recent Phase III study, researchers explored the efficacy and safety of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in elderly patients (aged ≥70 years) with previously untreated diffuse large B-cell lymphoma (DLBCL) (Abstract 7518). Read More >​


Therapeutic Potential of Glofitamab + Pola-R-CHP for DLBCL Patients​

New research presented at the 2023 ASCO Annual Meeting has unveiled encouraging findings regarding a novel combination therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study compared the effectiveness and safety of polatuzumab vedotin plus rituximab, cyclophosph​​amide, doxorubicin, and prednisone (Pola-R-CHP) with the standard treatment regimen R-CHOP as the first-line therapy (Abstract 7549). Read More >


​A Subgroup Analysis of Tafasitamab + Lenalidomide in Refractory DLBCL​

The Phase II L-MIND study has generated remarkable findings by investigating the combination of tafasitamab and lenalidomide as a treatment option for patients grappling with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Read More >

Real-World Outcomes in R/R DLBCL Patients Treated With Novel Therapies​

Recent research demonstrated that outcomes of novel therapies in the second- and third-line settings remain suboptimal among patients with diffuse large B-cell lymphoma (DLBCL). These findings, which were presented during the 2023 ASCO Annual Meeting, showed worse outcomes as patients progress through lines of therapy, as well as particularly poor outcomes when these agents are given after CAR-T therapy (Abstract 7552). Read More >


​​​A Retrospective Study on Survivors of Diffuse Large B-Cell Lymphoma

With improvements in treatment for diffuse large B-cell lymphoma (DLBCL), there have been a larger number of DLBCL survivors, and with the increased number of survivors, there has also been a corresponding increase in second primary malignancies (SPM) arising in these patients. Read More >

​​​Managing Patients With Peripheral T-Cell Lymphoma in the Frontline Setting​

During a 2023 ASCO Annual Meeting session on the “Management of Aggressive Lymphoma," Kerry J. Savage, MD, a medical oncologist at BC Cancer in Vancouver, British Columbia, discussed peripheral T-cell lymphoma (PTCL) and frontline treatment approaches, including the role of consolidative autologous stem cell transplant and the potential of personalized therapies for certain patients.​ Read More >​

​

​​​Treatment Selection for Patients With Primary CNS Lymphoma​

A panel discussion during the 2023 ASCO Annual Meeting explored possible therapeutic approaches for a patient with newly diagnosed primary CNS lymphoma, such as induction and consolidation strategies. Treatment options for relapsed and refractory disease were also discussed. Read More >

​

​​​​ Split-Dose R-CHOP for Older Diffuse Large B-Cell Lymphoma Patients​

Phase II data suggest that split-dose R-CHOP provides equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability for older patients with diffuse large B-cell lymphoma (DLBCL). Read More >

​​​​Unanswered Questions in DLBCL Management: Treatment for Relapsed Patients​​

At the 2023 ASCO Annual Meeting, Manali K. Kamdar, MD, Clinical Director of Lymphoma Services at The University of Colorado Anschutz Medical Campus, delivered a presentation during an education session, shedding light on the therapeutic challenges in aggressive lymphoma, specifically focusing on shared decision-making. Read More >

​
​​​​​​​​​